TransMedics [TMDX] vs Boston Scientific [BSX] Detailed Stock Comparison

TransMedics

NASDAQ
Loading...

Boston Scientific

NYSE
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: TransMedics wins in 9 metrics, Boston Scientific wins in 10 metrics, with 0 ties. Boston Scientific appears stronger overall.

View Metrics Details

Vital Metrics Comparison

MetricTransMedicsBoston ScientificBetter
P/E Ratio (TTM)58.4357.93Boston Scientific
Price-to-Book Ratio12.386.43Boston Scientific
Debt-to-Equity Ratio163.1053.09Boston Scientific
PEG Ratio0.330.40TransMedics
EV/EBITDA40.5033.14Boston Scientific
Profit Margin (TTM)13.49%13.55%Boston Scientific
Operating Margin (TTM)23.24%18.63%TransMedics
EBITDA Margin (TTM)23.24%18.63%TransMedics
Return on Equity28.21%11.55%TransMedics
Return on Assets (TTM)5.80%5.39%TransMedics
Free Cash Flow (TTM)$-80.94M$2.37BBoston Scientific
1-Year Return-15.73%11.02%Boston Scientific
Price-to-Sales Ratio (TTM)7.427.80TransMedics
Enterprise Value$4.06B$155.93BBoston Scientific
EV/Revenue Ratio7.658.43TransMedics
Gross Profit Margin (TTM)61.38%67.65%Boston Scientific
Revenue per Share (TTM)$16$13TransMedics
Earnings per Share (Diluted)$1.98$1.68TransMedics
Beta (Stock Volatility)2.070.61Boston Scientific
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends

TransMedics vs Boston Scientific Stock Performance Analysis

Loading Price Chart...

TransMedics
Boston Scientific
TransMedics Stock Overview | Boston Scientific Stock Overview

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
TransMedics-1.52%1.15%7.91%-8.98%64.76%71.32%
Boston Scientific-0.64%-0.35%-10.58%-6.87%5.64%8.19%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
TransMedics-15.73%191.53%742.68%359.40%359.40%359.40%
Boston Scientific11.02%141.87%151.56%466.49%1,472.36%305.28%

News Based Sentiment: TransMedics vs Boston Scientific

TransMedics

News based Sentiment: POSITIVE

TransMedics experienced a month of largely positive developments, including analyst upgrades, institutional investment, and a significant partnership, offsetting a slight downward revision in Q3 revenue projections. The company's strong long-term growth trajectory and innovative technology continue to attract investor interest, making it a compelling investment story.

View TransMedics News Sentiment Analysis

Boston Scientific

News based Sentiment: POSITIVE

October brought a wave of positive signals for Boston Scientific, including increased institutional investment, raised price targets from multiple firms, and a promising long-range plan. While insider selling remains a point to watch, the overall narrative is one of strong growth potential and investor confidence.

View Boston Scientific News Sentiment Analysis

Performance & Financial Health Analysis: TransMedics vs Boston Scientific

MetricTMDXBSX
Market Information
Market Cap i$4.00B$144.20B
Market Cap CategoryMid capLarge cap
10 Day Avg. Volume i716,26012,773,240
90 Day Avg. Volume i946,89310,174,867
Last Close$113.93$96.70
52 Week Range$55.00 - $145.50$80.64 - $109.50
% from 52W High-21.70%-11.69%
All-Time High$177.37 (Aug 19, 2024)$109.50 (Sep 09, 2025)
% from All-Time High-35.77%-11.69%
Growth Metrics
Quarterly Revenue Growth0.38%0.23%
Quarterly Earnings Growth1.86%1.46%
Financial Health
Profit Margin (TTM) i0.13%0.14%
Operating Margin (TTM) i0.23%0.19%
Return on Equity (TTM) i0.28%0.12%
Debt to Equity (MRQ) i163.1053.09
Cash & Liquidity
Book Value per Share (MRQ)$9.35$15.14
Cash per Share (MRQ)$11.75$0.36
Operating Cash Flow (TTM) i$115.27M$4.28B
Levered Free Cash Flow (TTM) i$-7,754,500$2.94B
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: TransMedics vs Boston Scientific

MetricTMDXBSX
Price Ratios
P/E Ratio (TTM) i58.4357.93
Forward P/E i70.1234.88
PEG Ratio i0.330.40
Price to Sales (TTM) i7.427.80
Price to Book (MRQ) i12.386.43
Market Capitalization
Market Capitalization i$4.00B$144.20B
Enterprise Value i$4.06B$155.93B
Enterprise Value Metrics
Enterprise to Revenue i7.658.43
Enterprise to EBITDA i40.5033.14
Risk & Other Metrics
Beta i2.070.61
Book Value per Share (MRQ) i$9.35$15.14

Financial Statements Comparison: TransMedics vs Boston Scientific

Financial Metrics

Loading Financial Charts...

Revenue

EBITDA

Shareholders Equity

Operating Margin

Free Cash Flow

Long Term Debt

Profit Margin

Current Ratio

Operating Cash Flow

Income Statement (MRQ)

Metric (MRQ)TMDXBSX
Revenue/Sales i$157.37M$4.66B
Cost of Goods Sold i$60.78M$1.45B
Gross Profit i$96.59M$3.21B
Research & Development i$15.93M$443.00M
Operating Income (EBIT) i$36.57M$937.00M
EBITDA i$45.79M$1.23B
Pre-Tax Income i$36.18M$805.00M
Income Tax i$1.28M$133.00M
Net Income (Profit) i$34.91M$672.00M

Balance Sheet & Liquidity Metrics (MRQ)

Metric (MRQ)TMDXBSX
Cash & Equivalents i$310.14M$725.00M
Total Current Assets i$505.92M$7.34B
Total Current Liabilities i$55.60M$5.06B
Long-Term Debt i$515.62M$10.93B
Total Shareholders Equity i$266.31M$22.45B
Retained Earnings i$-442.56M$3.35B
Property, Plant & Equipment i$40.54M$448.00M

Cash Flow Statement Comparison (MRQ)

Metric (MRQ)TMDXBSX
Operating Cash Flow i$354,000$513.00M
Capital Expenditures i$-27.04M$-187.00M
Free Cash Flow i$-29.89M$277.00M
Debt Repayment iN/A$-1.31B
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricTMDXBSX
Shares Short i8.39M19.02M
Short Ratio i8.812.76
Short % of Float i0.42%0.01%
Average Daily Volume (10 Day) i716,26012,773,240
Average Daily Volume (90 Day) i946,89310,174,867
Shares Outstanding i33.62M1.47B
Float Shares i32.96M1.48B
% Held by Insiders i0.03%0.00%
% Held by Institutions i1.10%0.94%

Dividend Analysis & Yield Comparison: TransMedics vs Boston Scientific

MetricTMDXBSX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A